Crown Bioscience, Inc, a JSR Life Sciences Company, and ERS Genomics Limited (‘ERS’) have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CRISPR/Cas9 for gene editing.

For details, please see the announcement from Crown Bioscience.

Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents